Intellus Advisors LLC Takes $270,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Intellus Advisors LLC bought a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,771 shares of the biopharmaceutical company's stock, valued at approximately $270,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Swedbank AB lifted its holdings in Bristol-Myers Squibb by 0.9% in the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock worth $162,440,000 after purchasing an additional 28,427 shares in the last quarter. United Bank raised its holdings in shares of Bristol-Myers Squibb by 2.7% in the 3rd quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock valued at $896,000 after purchasing an additional 456 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Bristol-Myers Squibb by 4.9% during the third quarter. Thrivent Financial for Lutherans now owns 116,801 shares of the biopharmaceutical company's stock worth $6,044,000 after buying an additional 5,407 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Bristol-Myers Squibb in the third quarter valued at about $3,579,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $29,000. 76.41% of the stock is owned by institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.09% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Cantor Fitzgerald lifted their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Truist Financial upped their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their price target for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Citigroup upped their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, Bank of America restated a "neutral" rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of "Hold" and a consensus target price of $57.86.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.02 during trading on Wednesday, reaching $59.18. The company had a trading volume of 11,579,179 shares, compared to its average volume of 12,172,370. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock's fifty day moving average price is $58.36 and its 200 day moving average price is $56.13. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The firm has a market capitalization of $120.08 billion, a price-to-earnings ratio of -13.39, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 4.19%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.